Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners already since it was envisioned and will soon have a fourth. But after six years, it is now officially open.
The company held a kickoff ceremony at the plant in Covington on Thursday, according to The Covington News. In an email, the company confirmed that the plant currently has about 900 employees and is expected to have about 1,500 when it is fully operational.
The 1 million-square-foot facility was announced in 2012 when Baxalta was still the drug unit of Baxter International. Baxter spun the drug unit off into Baxalta in 2014, and Shire bought Baxalta in a $32 billion deal in 2016 in a move to broaden its offerings. The plant is soon expected to have a fourth owner after Japan’s Takeda in May made a $62 billion deal to buy Dublin-based Shire.
Through all of that, patients have been “the ultimate inspiration for everything,” Carlos Soto, Shire’s vice president of manufacturing operations, said at the opening, the newspaper reported.
The company will make immunoglobulin products there to help patients with primary immune deficiency disorders. The company last year said it has filed its first submission to the FDA for the plant, seeking the transfer of production of Gammagard Liquid, a replacement therapy for primary humoral immunodeficiency. Shire in June won FDA approval for the product.
Shire expects to make a second submission to the FDA this year for development of its albumin therapy at the Covington facility. Shire’s albumin therapy is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions, the company said.
By Eric Palmer
Source: Fierce Pharma
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.
